Figure 2. Multiple Steps in Metastatic Progression
Although the poor prognosis signature has generally been interpreted as reflecting a difference in the tumor cells themselves, that is unlikely to be the full picture. An alternative, though not mutually results are in complete accord with the "preexisting metastatic variant" model of Fidler. But recall that the They found a set of four genes (CXCR4, IL-11, CTGF and MMP1) from their bone-specific metastatic signastarting cell line also showed the "poor prognosis" expression profile of van't Veer et al. Thus, it would seem ture that, when coexpressed with the gene for osteopontin (which is overexpressed in both bone and adrenal that both models are correct-in the same system (Figure 1c) . metastases), enhanced metastasis to bone. Each of the five genes, when expressed alone, was insufficient to Metastasis is a complex process involving many cell biological steps and presumably requiring many changes confer high metastatic potential, but, in various combinations, they elevated metastasis to levels similar to in gene expression. Depending on the analysis conducted, one can detect subsets of these changes. The those observed with the in vivo selected metastatic variants. Thus, the bone metastasis signature includes studies that looked for a gene expression signature for metastatic predisposition found one, whereas those that genes causally involved in metastasis to bone.
An important question is whether these highly metalooked for a signature characteristic of highly metastatic cells found a different subset. It is worth noting that static variants exist in the bulk population prior to in vivo selection. Kang et al. isolated subclones of the Kang et al. were able to distinguish cells with propensity to metastasize to bone or adrenal medulla and these MDA-MB-231 cell line in vitro, without any selection, and screened them for levels of expression of the five two groups showed differential gene expression. In an extensive analysis of human small cell lung cancer in genes they had analyzed for functional involvement. The diagnostic, prognostic, and therapeutic value of the predisposition signatures of primary tumors is largely unaffected by these mechanistic considerations. However, experimental analyses such as those of Kang et al. are an essential complement, allowing investigation of additional aspects of the metastatic process that cannot readily be revealed by retrospective analyses of human tumor samples, and we can expect many new insights to come from these two complementary approaches.
